| |
|
Bonny L. Dickinson, Ph.D.
- Assistant Professor, Department of Pediatrics
- Lousiana State University Health Science Center
|

|
| Curriculum
Vitae
|
Research Projects
| Transepithelial
Trafficking of IgG by FcRn |

The neonatal Fc gamma receptor, FcRn
Image courtesy of Dr. Pamela Bjorkman

FcRn-dependent IgG transcytosis
|
Epithelial barriers function to prevent the passive
movement of pathogens, toxins, and other noxious agents
into the sterile, internal environment of the body. At the
same time, however, the epithelium must selectively transport
macromolecules both into the body (the interstitium) and
in the opposite direction, delivering proteins onto mucosal
surfaces. One mechanism by which this transport occurs is
by moving cargos directly into and across the epithelial
cell in a process termed “transcytosis”, or
“transcellular transport”. The focus of our
research is to study the biology of the neonatal Fc gamma
receptor, FcRn, which functions to transcytose immunoglobulin
G (IgG) in both directions across epithelia.
We have recently discovered that FcRn is present in the
epithelial cells that form the lining of the gastrointestinal
tract. We have also shown that FcRn can transport IgG across
polarized epithelial cells, suggesting that this receptor
may be responsible for transport of IgG onto mucosal surfaces
where, like IgA, it may protect the host by immune exclusion.
It is also possible that FcRn transports IgG back across
the intestine thereby moving IgG-antigen complexes in the
opposite direction. In this way, FcRn may deliver lumenal
antigens bound to IgG to immune cells resident in the underlying
tissue such that an immune response may be mounted before
an infection can occur (immunosurveillance). |

Calmodulin regulates FcRn Transcytosis
|
To understand how FcRn affects mucosal immunity, it is necessary
to understand the molecular mechanisms by which the receptor
traffics in polarized epithelial cells. To do this, we have
expressed human FcRn in MDCK cells and demonstrate FcRn-dependent
bidirectional transcytosis of IgG across cell monolayers.
With this model system, we have discovered that a calcium
sensing protein, calmodulin, binds to FcRn in a calcium
dependent and reversible fashion. FcRn-mutants with single
residue substitutions that cannot bind calmodulin transport
IgG more slowly across MDCK monolayers than wild-type FcRn,
at rates similar to FcRn-mutants lacking the cytoplasmic
tail entirely. These data suggest that calmodulin may regulate
the trafficking of FcRn in polarized epithelial cells and
thus mediate the transport of IgG across mucosal surfaces.
|
We are now working to identify the exact step in trafficking
affected by calmodulin. Specifically, our studies will determine
whether calmodulin (1) is the trigger that prevents the lysosomal
degradation of FcRn, (2) mediates the exocytosis of transcytotic
vesicles containing FcRn, (3) signals FcRn to leave the recycling
endosome and enter the transcytotic pathway, (4) controls
the phosphorylation state of FcRn and thus trafficking in
one or more of these pathways, or (5) regulates association
of the FcRn cytoplasmic tail with biological membranes. These
studies will identify a mechanism for the physiologic regulation
of transepithelial IgG transport by cycles of calmodulin binding
to FcRn. |
|
Mechanism of the cholera toxin and heat-labile enterotoxin
adjuvanticity
|

Structure of CT and LT
Image courtesy of Dr. Wim Hol
and Dr. Ethan Merritt
|
A fundamental principle of mammalian physiology is the
formation and maintenance of epithelial barriers. Such
barriers line the tissues of organ systems that interface
with the environment and are found at all mucosal surfaces
including the gastrointestinal, respiratory, and genitourinary
systems. Structurally, these barriers are created by a
continuous monolayer of polarized epithelial cells with
distinct apical and basolateral membrane domains, each
containing unique protein and lipid components. This polarity
in cell structure defines the opposing lumenal (apical)
and serosal (basolateral) functions of mucosal surfaces
and accounts for the vectorial transport of specific solutes,
gases, and water across epithelial barriers such as that
found in the intestine, lung, and genitourinary tract.
To generate barrier function, the individual epithelial
cells lining these tissues must also assemble circumferential
intercellular tight junctions that seal one cell to another.
The tight junction represents the rate-limiting barrier
that restricts passive diffusion and convection of solutes,
molecules, and water between cells. In this way, the single
cell thick monolayer that defines the mucosal surface
functions to establish and maintain biological homeostasis
between the outside and inside environments. Ultimately,
the epithelial barrier protects the host from microbial
invasion and penetration of other noxious agents. However,
some proteins, such as bacterial toxins, are able to breech
this barrier to cause disease.
|
|

CT and LT function as potent
mucosal adjuvants
|
The cholera enterotoxin (CT) and the related heat-labile
enterotoxin (LT) produced by Vibrio cholerae and enterotoxigenic
strains of Escherichia coli, respectively, must breech the
intestinal epithelial barrier to cause disease. Both toxins
enter intestinal epithelial cells and in doing so, stimulate
chloride and water secretion into the intestinal lumen resulting
in the watery diarrhea associated with cholera and traveler’s
diarrhea. These toxins also cross the mucosal barrier by
transcytosis and enter the lamina propria as fully folded
and functional proteins.
It is well accepted that CT and LT represent the most potent
mucosal immunogens and adjuvants recognized to date. While
the mechanism by which CT and LT function as mucosal adjuvants
is unknown, their adjuvant properties depends on toxin transcytosis
across intestinal epithelial cells, an event that facilitates
toxin access to relevant antigen-presenting cells in the
lamina propria. We are examining the immunological consequences
of toxin transcytosis to determine how CT and LT function
as mucosal adjuvants so that “smart” drugs and
pharmaceuticals may be developed to mimic the adjuvant effect
observed with these toxins without the resulting enterotoxicity. |
Dickinson
Lab
|
|